Teva FDA approval for WELTRUZA once-monthly injectable olanzapine
Teva announced U.S. FDA approval of WELTRUZA™ (olanzapine) for extended-release injectable suspension, described as a once-monthly subcutaneous injectable for adults with schizophrenia.
Story updates
11:01:58 AM UTC
SquawkNews
Teva received FDA approval for WELTRUZA, the first once-monthly subcutaneous long-acting olanzapine for adults with schizophrenia, available in three strengths with no loading, oral supplementation, or post-injection monitoring required.Material DetailsContext by AI AnalystThis is a mid-cycle valid…